Certolizumab pegol
Based on 2 publication(s) in Google Scholar
Certolizumab pegol (Certolizumab) is a recombinant, polyethylene glycosylated, antigen-binding fragment of a humanized monoclonal antibody that selectively targets and neutralizes tumour necrosis factor-α (TNF-α). Certolizumab pegol can be used for rheumatoid arthritis and Crohn disease research.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.30%
- CAS. Nr.: 428863-50-7
- Molecular Weight:91 kDa
-
Speicherung:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Certolizumab pegol
MoreAlle TNF Receptor Isoform-spezifische Produkte anzeigen
More
Biologische Aktivität
Fab'-G1-kappa
Human
TNF
Certolizumab pegol (Certolizumab) neutralizes soluble TNFα with an IC90 of 3 ng/mL[2].
Certolizumab pegol (0-100 μg/mL, 1 h) completely inhibits subsequent production of IL-1β in response to LPS in human monocytes[2].
Certolizumab pegol does not mediate complement-dependent cytotoxicity (CDC) or antibody-dependent cell-mediated cytotoxicity (ADCC)[2].
Certolizumab pegol does not induce apoptosis of activated human monocytes or peripheral blood lymphocytes (PBLs) or result in degranulation or loss of cell membrane integrity in polymorphonuclear cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Healthy Wistar Albino male rats weighing 180 to 200 g, acute edematous pancreatitis was induced via intraperitoneal injection of 80 μg/kg Cerulein (HY-A0190) (20 μg/kg, 4 times at 1-hour intervals)[3]
-
Dosage:10 μg
-
Administration:Intraperitoneal administration, single dose
-
Result:Significantly decreased the serum levels of amylase, lipase, and lactate dehydrogenase. Histopathological edema, hemorrhage, parenchymal necrosis, and infiltration scores were also decreased, along with a decrease in malondialdehyde, myeloperoxidase, TNF-α, and caspase-3 activities.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Fab'-G1-kappa
ELISA, FACS, Functional assay
-
Immobilized TNF-alpha/TNFSF2 Protein, Human (HY-P7058) can bind Certolizumab pegol. The EC50 for this effect is 238 ng/mL. -
Flow cytometric analysis of 1.5X106 RAW264.7 cells treated with 1µg/mL LPS for 24h with Certolizumab pegol (HY-P9953, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS. Nr. 428863-50-7
-
Appearance Liquid
-
Molecular Weight 91 kDa
-
Color Colorless to light yellow
-
SMILES
[Certolizumab pegol]
-
Synonyms
Certolizumab; CDP870
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Speicherung
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
Chin Neurosurg J
2025 Dec 12;11(1):32. PMID: 41387915 -
Reinheit & Dokumentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Verweise
[1]. Deeks ED. Certolizumab pegol: a review of its use in the management of rheumatoid arthritis. Drugs. 2013 Jan;73(1):75-97. [Content Brief]
[2]. Nesbitt A, et al. Mechanism of action of certolizumab pegol (CDP870): in vitro comparison with other anti-tumor necrosis factor alpha agents. Inflamm Bowel Dis. 2007 Nov;13(11):1323-32. [Content Brief]
[3]. Kosekli MA, et al. Effects of Certolizumab on Cerulein-Induced Acute Pancreatitis in Rats. Pancreas. 2016 Sep;45(8):1120-5. [Content Brief]
Calculators
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Certolizumab pegol Related Classifications
HY-P9953 Related Classifications
Powered by Bioz